Schering-Plough's Temodar Gets Priority Review For First-Line Glioma
This article was originally published in The Pink Sheet Daily
Executive Summary
The supplemental application has a user fee goal date of March 2005. Phase II/III trials of the oral cytotoxic alkylating agent are ongoing for treatment of brain metastases from various cancers.
You may also be interested in...
Schering-Plough's Temodar Clears FDA For First-Line Use In Glioblastoma
Approval of temozolomide was based on a Phase III trial that demonstrated a statistically significant survival benefit in combination with radiotherapy versus radiotherapy alone. Temodar also received full approval for its original indication of anaplastic astrocytoma.
Schering-Plough's Temodar Clears FDA For First-Line Use In Glioblastoma
Approval of temozolomide was based on a Phase III trial that demonstrated a statistically significant survival benefit in combination with radiotherapy versus radiotherapy alone. Temodar also received full approval for its original indication of anaplastic astrocytoma.
Guilford CEO Search Ends With Appointment Of Bristol Exec
Bristol VP-Strategy Dean Mitchell will join Guilford Dec. 1, replacing company co-founder Craig Smith, who is retiring. Mitchell is expected to oversee a busy period for the company, which anticipates results from up to 13 late-stage clinical trials during the next 12-18 months.